Compare BioNTech SE - ADR (BNTX) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Riot Platforms Inc — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Riot Platforms Inc trades at $20.31 (market cap $7.59B). The key difference: BioNTech SE - ADR is far larger — about 3.1× Riot Platforms Inc's market cap, and Riot Platforms Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | RIOT | |
|---|---|---|
Market Cap | $23.31B | $7.59B |
Sector | Health | Technology |
52-Week High | $119.34 | $28.67 |
52-Week Low | $83.89 | $11.33 |
Enterprise Value | $6.60B | $8.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
RIOT Platforms trades at $20.32, up 4.74% today, amid strong technical resistance near $21-$23 levels. The stock shows bearish momentum despite recent positive news about a $9.1 billion AI infrastructure deal with Anthropic. Fundamentally, the company continues to post significant losses with a -196.28% net income margin, though revenue growth remains steady at $675 million projected for 2026.
While analyst consensus remains overwhelmingly bullish with a $33.40 price target, investors face substantial execution risks as RIOT transitions from bitcoin mining to AI infrastructure. The company's persistent negative cash flow and high valuation multiples present challenges despite the transformative potential of the Anthropic partnership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
